Among the planet 's most popular drugs in 2010, PIavix, appears to have a limited future. Its patent was due to expire soon and lately new data had been found which indicated that a small subset of the population would be in danger for stroke, heart attack or death if they took PIavix. As a consequence the FDA had added a black box warning- the most severe of the bureau -- in 2010 to the label of Plavix. Additionally, it was discovered that the common mixture of Plavix and Prilosec, an over-the-counter drug, could adversely impact patients. How might the prospective competitors of Plavix utilize Plavix's miscellaneous history to their advantage? How should genotyping be incorporated into the clinical care of patients in the light of emerging knowledge?
Plavix Drugs in the Age of Personalized Medicine case study solution
PUBLICATION DATE: October 22, 2010 PRODUCT #: 811001-PDF-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Governance and Talent Management in a Professional Services Firm
The Bottom-line Benefits of Ethics Code Commitment
Lessons from Pharmaceutical Product Litigation: Merck and the Vioxx Withdrawal Cona & McDarby vs. Merck Video Supplement
ATH MicroTechnologies: Making the Numbers
Critical Competitive Strategy Issues Every Entrepreneur Should Consider Before Going into Business
Gary Rodkin at Pepsi-Cola North America (B)
The Rise and Fall of Iridium
Massachusetts Financial Services (MFS)
SHANGHAI PHARMACEUTICALS
Chandpur Enterprises Limited, Steel Division
